Premature ejaculation treatment market to reach over $1.3 billion by 2017

In 2010 the premature ejaculation treatment market was estimated to be worth $684 million, according to a new research report available on It is expected to increase in value by around 10.3% p/a to 2017, reaching $1.3 billion, on account of the anticipated US and European approval of Priligy (dapoxetine).

Premature Ejaculation (PE) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

The premature ejaculation medication market represents a distinct unmet treatment need, as there are very few therapies in development, and those that are in use tend to be off-label (i.e., prescribed for an unapproved indication), such as SSRIs.

Forthcoming PE drugs include Priligy and topically applied PSD502/TEMPE. The market for PE therapeutics is highly competitive, as only Priligy is approved for treatment (and not in all countries).

Off-label drugs administered for the treatment of premature ejaculation include Prozac (fluoxetine), Zoloft (sertraline) and Paxil (paroxetine).

At present, physicians' preferred treatment for premature ejaculation is a behavioural method termed 'stop and squeeze', which yields satisfactory results and has no side effects.

It is estimated that the premature ejaculation market was valued at US$684 million in 2010, with the sector forecast to expand at 10.3% compound annual growth rate to 2017. By the end of 2017, the premature ejaculation market is forecast to be valued at US$1.3 billion. The expected approval of the branded drug Priligy (dapoxetine) and the prevalence of PE in the male population is expected to drive this growth.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
New research finds father's prenatal mental health may benefit child's behavior and IQ